Bloomberg: Samsung and WuXi Plan IPOs for their Biologic CMOs

Two Asian biologic contract manufacturing organizations, Samsung Biologics and WuXi Biologics, have IPOs in the works. Samsung announced a $2 billion Korean IPO in September, while WuXi plans a $500 million Hong Kong initial offering early next year. The Samsung transaction has been officially announced; a Bloomberg article predicted the WuXi IPO, based on a report from an unidentified insider. The two companies are vying to become leaders in biologics, a sector of the greater pharma market that will be just as important as small molecule drugs in less than ten years. More details.... Share this with colleagues: // //